glp-1 trial results today Emerging Frontiers in Therapeutics: A Comprehensive Evidence Base (2025) Many people remain excluded from

Ready to transform your body

But first, this edition of the newsletter is brought to you by Embla

Other patients choose evening injection to minimize appetite suppression during their workday, though clinical evidence shows no pharmacological advantage to either timing

The GLP-1 Effect: Market Penetration In the UK, 4.2 million adultsnearly 1 in 10had recently used a GLP-1 medication or expressed interest in doing so as of early 2025 Two in five overweight Britons (38%) express interest in using GLP-1s for weight loss when informed about the drugs Across Europe, the GLP-1 market is valued at 9.62 billion in 2025, with robust growth expected due to rising obesity and diabetes rates, improved access, and strong healthcare infrastructure in markets like Germany, France, and the UK Social acceptance is rising, and insurance coverage is likely to expand, further accelerating adoption